Top 50 global pharmaceutical companies and their best selling drugs in 2018 Pfizer ranks first

Source: CPHI pharmaceutical online 2018-06-13 recently, the latest edition of the top 50 global pharmaceutical companies in 2018 was published by pharmaceutical executive magazine in the United States Pharm exec ranks among the top 50 pharmaceutical companies in terms of global prescription drug sales of each biopharmaceutical company every year Most companies maintain last year's ranking, but they also need to consider a more challenging business environment and look for new growth opportunities in the future market People in the industry think that the sales volume on which the ranking is based does not include businesses such as consumer health products, which is closer to the real strength of pharmaceutical enterprises In recent years, great changes have taken place in the biopharmaceutical and healthcare markets From the continuous update of treatment progress to the pressure of drug price and business competition, pharm exec's latest list of top 50 global biopharmaceutical sales leaders in 2018 is still very stable Pfizer's top 10 list is in line with last year's The sales revenue of prescription drugs, which accounts for the backbone of the sales of pharmaceutical giants, increased only in part, among which Johnson & Johnson and Roche increased the most, reaching 7.6% and 5.5% respectively In terms of collecting annual data (now in its 18th year), pharm exec once again teamed up with evaluate Ltd., a life science market intelligence company Sanofi, the fifth largest seller by sales, has seen its R & D spending rise the most in the top ten, up 46% from the same period last year The Paris based company currently has 28 projects in phase 3 clinical development or in line with regulators for approval, and six projects in phase 2 or phase 3 clinical trials for rare diseases In general, in the R & D stage and commercial sales expansion stage, the industry investment of rare disease drugs is increasing, which is not a secret in the pharmaceutical industry According to reports, the FDA granted 77 orphan drug qualifications last year, and received 476 orphan drug certification applications Among the top 20 pharmaceutical giants in this list, some companies' R & D expenses increased significantly higher than others, including Gilead Sciences increased by 26.8%, Allergan increased by 69.5%, Teva pharmaceutical even more than doubled, and R & D expenses increased to $4.97 billion In 2017, the profits of biopharmaceuticals were affected by the US tax system reform, which restricted the overall profits of some enterprises, and pharmaceutical companies had to pay a large number of one-time fees with regulatory reform However, looking forward to the future, the reform of the tax system, which reduces the corporate income tax in the United States to 21%, is expected to stimulate the recovery of M & A activities in the field of biomedicine So far this year, major pharmaceutical companies have announced several small acquisitions Such deals and subsequent larger global acquisitions, including Takeda's $62 billion takeover of shire last month, will affect the ranking of pharma 50 next year The Takeda shire merger is likely to put new companies in the top 10, the report said International Trade and other policies to curb drug pricing may affect the competition of new drugs For example, the U.S government's new reform pricing strategy, but there is no specific timetable for the implementation of the policy Sales of proprietary drugs are likely to continue to grow across the drug market - a factor contributing to the increase in prescription drug costs, although some reports predict that spending on proprietary drugs in developed countries will decline in the short term this year and remain stable thereafter In addition to maintaining the continuous listing of specialty drugs in the R & D pipeline and carrying out marketing innovation, the global talent competition of pharmaceutical enterprises will become increasingly fierce In the new market environment, enterprises need people with more vision and leadership to steer the company's future development direction Finally, let's take a look at the top 50 biopharmaceutical companies in terms of sales volume, R & D investment and best-selling drugs.